Thomas K. Equels, Executive Vice Chairman/CEO/Pres at HEMISPHERX BIOPHARMA INC (HEB), bought 20,000 shares at $0.19 ($4K) on 2018-11-30, disclosed to the SEC on 2018-12-03.
Open-market purchase of $4k HEB by Executive Vice Chairman/CEO/Pres. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.19 | 9,557 | $2K | 47.0% |
| 2 | $0.19 | 50 | $10 | 0.2% |
| 3 | $0.19 | 300 | $57 | 1.5% |
| 4 | $0.19 | 334 | $63 | 1.6% |
| 5 | $0.19 | 1,354 | $257 | 6.7% |
| 6 | $0.19 | 2,400 |
| $456 |
| 11.8% |
| 7 | $0.19 | 5 | $1 | 0.0% |
| 8 | $0.20 | 6,000 | $1K | 31.1% |
| Total | $0.19 avg | 20,000 | $4K | 100% |
| Filing → |
| AIM | BUY | 2020-12-17 | $25K | — | Filing → |
| AIM | BUY | 2020-09-03 | $25K | — | Filing → |
| AIM | BUY | 2020-08-21 | $25K | — | Filing → |